

Highlights of This Issue 2097

SPECIAL FEATURES

CCR Translations

- 2099** Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors
Eneda Toska and José Baselga
See related article, p. 2250
- 2102** Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Kurt A. Schalper, Edward Kaftan, and Roy S. Herbst
See related article, p. 2261


CCR New Strategies

- 2105** New Strategies in Breast Cancer: Immunotherapy
Lajos Pusztai, Thomas Karn, Anton Safonov, Maysa M. Abu-Khalaf, and Giampaolo Bianchini

CCR Perspectives in Regulatory Science and Policy

- 2111** The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative
Jonathan P. Jarow, Sandra Casak, Meredith Chuk, Lori A. Ehrlich, and Sean Khozin

Statistics in Clinical Cancer Research

- 2114** Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
 Alexia Iasonos, Paul B. Chapman, and Jaya M. Satagopan

Molecular Pathways

- 2121** Molecular Pathways: Immunosuppressive Roles of IRE1 α -XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment
Juan R. Cubillos-Ruiz, Sarah E. Bettigole, and Laurie H. Glimcher

Perspectives

- 2127** Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
 Desamparados Roda, Begoña Jimenez, and Udai Banerji
- 2133** Defining the Value of a Comparative Approach to Cancer Drug Development
 Amy K. LeBlanc, Christina N. Mazcko, and Chand Khanna

CANCER THERAPY: CLINICAL

- 2139** A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
 Ji Yun Lee, Jong-Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Bo Mi Ku, Jiae Koh, Yeon-Hee Bae, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, and Myung-Ju Ahn
- 2146** A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
 Laura W. Goff, Roger B. Cohen, Jordan D. Berlin, Filippo G. de Braud, Andrej Lyshchik, Cristina Noberasco, Francesco Bertolini, Marina Carpentieri, Corrado Gallo Stampino, Antonello Abbattista, Erjan Wang, and Hossein Borghaei
- 2155** Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
 Gerty Schreibelt, Kalijn F. Bol, Harm Westdorp, Florian Wimmers, Erik H.J.G. Aarntzen, Tjitske Duiveman-de Boer, Mandy W.M.M. van de Rakt, Nicole M. Scharenborg, Annemiek J. de Boer, Jeanette M. Pots, Michel A.M. Olde Nordkamp, Tom G.M. van Oorschot, Jurjen Tel, Gregor Winkels, Katja Petry, Willeke A.M. Blokk, Michelle M. van Rossum, Marieke E.B. Welzen, Roel D.M. Mus, Sandra A.J. Croockewit, Rutger H.T. Koonstra, Joannes F.M. Jacobs, Sander Kelderman, Christian U. Blank, Winald R. Gerritsen, Cornelis J.A. Punt, Carl G. Figdor, and I. Jolanda M. de Vries

Table of Contents

PERSONALIZED MEDICINE AND IMAGING

- 2167** Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer
Jian Li, Changkun Ye, and Ulrich R. Mansmann
- 2177** Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Aaron S. Mansfield, Stephen J. Murphy, Tobias Peikert, Eunhee S. Yi, George Vasmatazis, Dennis A. Wigle, and Marie Christine Aubry
- 2183** Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors
Gregory V. Kryukov, Craig M. Bielski, Kaitlin Samocha, Menachem Fromer, Sara Seepo, Carleen Gentry, Benjamin Neale, Levi A. Garraway, Christopher J. Sweeney, Mary-Ellen Taplin, and Eliezer M. Van Allen
- 2190** Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[¹⁸F]fluoroethyl)-L-Tyrosine PET
Sied Kebir, Rolf Fimmers, Norbert Galldiks, Niklas Schäfer, Frederic Mack, Christina Schaub, Moritz Stuplich, Michael Niessen, Theophilos Tzaridis, Matthias Simon, Gabriele Stoffels, Karl-Josef Langen, Björn Scheffler, Martin Glas, and Ulrich Herrlinger
- 2197** Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel *In Vivo* Device for Capturing Circulating Tumor Cells
Tobias M. Gorges, Nicole Penkalla, Thomas Schalk, Simon A. Joosse, Sabine Riethdorf, Johannes Tucholski, Klaus Lücke, Harriet Wikman, Stephen Jackson, Nora Brychta, Oliver von Ahsen, Christian Schumann, Thomas Krahn, and Klaus Pantel

CANCER THERAPY: PRECLINICAL

- 2207** The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNF α /IL17 Dependent
Vy Phan-Lai, Yushe Dang, Ekram Gad, Jennifer Childs, and Mary L. Disis
- 2217** The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
Naiara Martínez-Vélez, Enric Xipell, Beatriz Vera, Arlet Acanda de la Rocha, Marta Zalacain, Lucía Marrodán, Marisol Gonzalez-Huarriz, Gemma Toledo, Manel Cascallo, Ramón Alemany, Ana Patiño, and Marta M. Alonso

- 2226** Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8⁺ T Cells
Julie S. Nielsen, Colin G. Sedgwick, Aniqah Shahid, Zusheng Zong, Zabrina L. Brumme, Stephen Yu, Lewis Liu, David R. Kroeger, Steven P. Treon, Joseph M. Connors, Randy D. Gascoyne, Brian R. Berry, Marco A. Marra, Ryan D. Morin, Nicol Macpherson, and Brad H. Nelson
- 2237** Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
Luke D. Rothmel, Arvind C. Sabesan, Daniel J. Stephens, Smita S. Chandran, Biman C. Paria, Abhishek K. Srivastava, Robert Somerville, John R. Wunderlich, Chyi-Chia R. Lee, Liqiang Xi, Trinh H. Pham, Mark Raffeld, Parthav Jailwala, Manjula Kasoji, and Udai S. Kammula
- 2250** Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, *PIK3CA*-Mutant Breast Cancer
Wei Yang, Sarah R. Hosford, Lloye M. Dillon, Kevin Shee, Stephanie C. Liu, Jennifer R. Bean, Laurent Salphati, Jodie Pang, Xiaolin Zhang, Michelle A. Nannini, Eugene Demidenko, Darcy Bates, Lionel D. Lewis, Jonathan D. Marotti, Alan R. Eastman, and Todd W. Miller
See related commentary, p. 2099

BIOLOGY OF HUMAN TUMORS

- 2261** Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock, Bhumsuk Keam, Sehui Kim, Ju-Seog Lee, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, and Dae Seog Heo
See related commentary, p. 2102
- 2271** Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy
Stefania Catalano, Antonella Campana, Cinzia Giordano, Balázs Györfy, Roberta Tarallo, Antonio Rinaldi, Giuseppina Bruno, Aurora Ferraro, Francesco Romeo, Marilena Lanzino, Fabio Naro, Daniela Bonofiglio, Sebastiano Andò, and Ines Barone
- 2283** Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer
Neil M. Iyengar, Xi Kathy Zhou, Ayca Guçalp, Patrick G. Morris, Louise R. Howe, Dilip D. Giri, Monica Morrow, Hanhan Wang, Michael Pollak, Lee W. Jones, Clifford A. Hudis, and Andrew J. Dannenberg

Table of Contents

2290 Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas



Ryan D. Morin, Sarit Assouline, Miguel Alcaide, Arezoo Mohajeri, Rebecca L. Johnston, Lauren Chong, Jasleen Grewal, Stephen Yu, Daniel Fornika, Kevin Bushell, Torsten Holm Nielsen, Tina Petrogiannis-Haliotis, Michael Crump, Axel Tosikyan, Bruno M. Grande, David MacDonald, Caroline Rousseau, Maryam Bayat, Pierre Sesques, Remi Froment, Marco Albuquerque, Yury Monczak, Kathleen Klein Oros, Celia Greenwood, Yasser Riazalhosseini, Madeleine Arseneault, Errol Camlioglu, André Constantin, Qiang Pan-Hammarstrom, Roujun Peng, Koren K. Mann, and Nathalie A. Johnson

2301 Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas

Rodrigo A. Toledo, Yuejuan Qin, Zi-Ming Cheng, Qing Gao, Shintaro Iwata, Gustavo M. Silva, Manju L. Prasad, I. Tolgay Ocal, Sarika Rao, Neil Aronin, Marta Barontini, Jan Bruder, Robert L. Reddick, Yidong Chen, Ricardo C.T. Aguiar, and Patricia L.M. Dahia

LETTER TO THE EDITOR

- 2311 Significance of FcγRIIIa-V158F Polymorphism—Letter
Janardan P. Pandey

CORRECTIONS

- 2312 Correction: Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- 2313 Correction: Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover image shows the recurrence of mutations, represented by colored squares, affecting known lymphoma-related genes among a cohort of relapsed and treatment-refractory DLBCL tumors subjected to exome sequencing. Each column corresponds to an individual patient with transformed lymphomas positioned on the left and *de novo* DLBCL toward the right. Each row is a gene, with the most frequently mutated genes (TP53, MLL2, CREBBP, MLL3, and STAT6) towards the top. Protein-altering mutations of different categories are indicated by color. Noncoding mutations are omitted, with the exception of mutations affecting the microRNA gene MIR142 (purple). For details see the article by Morin and colleagues on page 2290 of this issue.

